score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability - High	Guideline			Rearrangement	COL1A1	Fusion	COL1A1--BCL2L2-PABPN1			0.0	0.0		Investigate Actionability - High	Imatinib	Targeted therapy	Imatinib has shown clinical activity against localized and metastatic DFSP tumors containing t(17;22)(q22;q13).	National Comprehensive Cancer Network. Dermatofibrosarcoma NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf												0				COL1A1--BCL2L2-PABPN1 Fusion	0.0	TP_2060		
Investigate Actionability - High	Inferential			Mutational Signature	COSMIC Signature 3		0.402						Investigate Actionability - High	Platinum	Chemotherapy	Responders to platinum based chemotherapy exhibit COSMIC signature 3 (HR signature) mutations in pancreatic cancer.	Alexandrov LB, Nik-zainal S, Siu HC, Leung SY, Stratton MR. A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun. 2015;6:8683.	https://doi.org/10.1038/ncomms9683												0				COSMIC Signature 3 (40%)		TP_2060		
Investigate Actionability - High		Clinical evidence	Clinical trial	Somatic Variant	TP53	Frameshift	p.DRNTFRHSVVV208fs	0.0374	187.0	0.0	0.0								Investigate Actionability - High	Lenalidomide	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability - Low	0.0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310	0	0.0	0.0	0.0	TP53 p.DRNTFRHSVVV208fs (Frameshift)		TP_2060	TP_2060-TM	TP_2060-NB
Investigate Actionability - High		Clinical evidence		Somatic Variant	AR	Missense	p.W742C	0.1042	96.0	0.0	0.0								Investigate Actionability - High	Abiraterone	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220						0	28.0	0.3214	0.3848	AR p.W742C (Missense)		TP_2060	TP_2060-TM	TP_2060-NB
Investigate Actionability - Low	Clinical evidence			Somatic Variant	PBRM1	Missense	p.R725G	0.1244	394.0	0.0	0.0		Investigate Actionability - Low	Nivolumab	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951												0	0.0	0.0	0.0	PBRM1 p.R725G (Missense)		TP_2060	TP_2060-TM	TP_2060-NB
Biologically Relevant				Microsatellite Stability	Supporting variants		MSH3 p.63_64insAAP (Insertion)																							0				Supporting variants: MSH3 p.63_64insAAP (Insertion)		TP_2060		
Biologically Relevant				Mutational Signature	COSMIC Signature 1		0.228																							0				COSMIC Signature 1 (23%)		TP_2060		
